Moss, 9.5.2019
Gentian Diagnostics AS announces its results for the first quarter of 2019. The highlights include:
- Good start to the new fiscal year with sales revenues of MNOK 10.6 for the quarter.
- Record sales achieved for fCAL®turbo, our innovative biomarker for the diagnosis of inflammatory bowel disease.
- New scientific study results confirm GCAL as a promising biomarker for the diagnosis of bacterial infections.
Please find the report and results presentation enclosed. The documents is also available on Oslo Børs.
Q1 2019 GD Interim presentation
Q1 2019 GD Interim report
For further information, please contact:
Hilja Ibert
CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242
Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone: +47 919 06 525
MeldingsID: 476431
UtstederID: GENT-ME
Instrument: GENT-ME
Marked: Merkur Market
Kategori: HALVÅRSRAPPORTER OG REVISJONSBERETNINGER / UTTALELSER OM FORENKLET REVISORKONTROLL